On June 29, 2020 Exicure, Inc. (NASDAQ:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) technology, reported that it has been added to the Russell 2000 index. This addition was effective June 26, 2020 (Press release, Exicure, JUN 29, 2020, View Source [SID1234561541]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that Exicure has reached this important milestone," said Dr. David Giljohann, Exicure’s Chief Executive Officer. "We look forward to telling a growing set of investors about our clinical progress in neurology, oncology, and ophthalmology using our genetic medicines," concluded Dr. Giljohann.

The Russell U.S. Indexes are widely used by investment managers and institutional investors for passive funds and investment products and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell U.S. Indexes. For more information on the Russell Indexes, please visit the "Russell Reconstitution" section on the FTSE Russell website at www.ftserussell.com.